Cost-effectiveness analysis of ready-to-use esmolol in the treatment of critically ill patients
OBJECTIVE To evaluate the economics of ready-to-use esmolol compared with other non-ready-to-use ultra-short-acting β-blockers for the treatment of patients with critical illnesses represented by supraventricular tachycardia and provide references for rational clinical medication.METHODS A decision tree model was constructed from the perspective of Chinese healthcare system to assess the health outcomes and costs of using ready-to-use esmolol versus esmolol injection or landiolol in the perioperative period.Clinical data were gathered from clinical studies and expert survey in the Chinese context.Cost data were derived from published literature and expert survey.One-way sensitivity analysis and probabilistic sensitivity analysis were con-ducted to validate the robustness of the results.RESULTS The primary analysis indicated that compared to esmolol in glass ampoule form,ready-to-use esmolol led to a 0.12 times reduction in the occurrence of dosage form-related safety events,result-ing in cost savings of 203.79 CNY.This included 181.90 CNY savings in drug costs,10.00 CNY in medical consumables costs,5.45 CNY in saline configuration costs,and 6.44 CNY in dosage form-related safety event management costs,respectively.In comparison to landiolol,ready-to-use esmolol reduced the occurrence of adverse drug reactions by 0.04 times,resulting in cost savings of 2 347.20 CNY.This included 2 328.40 CNY in drug costs,10.00 CNY in medical consumables costs,5.45 CNY in saline configuration costs,and 3.35 CNY in costs related to adverse drug reaction treatment.Sensitivity analysis confirmed the robustness of the results.CONCLUSION Compared to esmolol in glass ampoule form and landiolol,ready-to-use esmolol is more economical and has a definite advantage in the treatment of critically ill patients represented by supraventricular tachycardia.
esmolol hydrochloride and sodium chloride injectionesmolol hydrochloride injectionlandiolol hydrochloride for injectiontachyarrhythmiaperioperative hypertensioncost effectiveness analysis
NETL
